CMBA
MIRM icon

C.M. Bidwell & Associates’s Mirum Pharmaceuticals MIRM Stock Holding History

C.M. Bidwell & Associates’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-58
Closed -$4.58K – 509
2025
Q4 		$4.58K Buy
+58
New +$4.16K ﹤0.01% 338

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

C.M. Bidwell & Associates's MIRM Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Mirum Pharmaceuticals (MIRM) in Q1 2026, closing a stake of 58 shares — an estimated $4.58K sold.

C.M. Bidwell & Associates first reported a position in MIRM in Q4 2025 and held it in 1 quarter. The position peaked at $4.58K in Q4 2025. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

  • C.M. Bidwell & Associates reported no remaining Mirum Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 58 Mirum Pharmaceuticals shares in Q1 2026, an estimated $4.58K.
  • C.M. Bidwell & Associates first reported a position in Mirum Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Mirum Pharmaceuticals position peaked at $4.58K in Q4 2025.
  • 311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.